Krystal Biotech, Inc. KRYS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s EBITDA margin?
- Krystal Biotech, Inc. (KRYS) reported EBITDA margin of 44.2% in Q1 2026.
- How has Krystal Biotech, Inc.'s EBITDA margin changed year-over-year?
- Krystal Biotech, Inc.'s EBITDA margin increased by 28.7% year-over-year, from 34.4% to 44.2%.
- What is the long-term trend for Krystal Biotech, Inc.'s EBITDA margin?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s EBITDA margin has grown at a -55.3% compound annual growth rate (CAGR), from -214.5% to 42.9%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.